´ëÇѺñ´¢±âÁ¾¾çÇÐȸ The 21st KUOS Multidisciplinary Conference(2ÀÏÂ÷) : 2023-03-25 |
|
´ëÇѺñ´¢±âÁ¾¾çÇÐȸ The 21st KUOS Multidisciplinary Conference(2ÀÏÂ÷) : 2023-03-25 ±³À°ÁÖÁ¦ : The 21st KUOS Multidisciplinary Conference(2ÀÏÂ÷) ÁÖÃÖ±â°ü : ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ À̸ÞÀÏ : app@app2010.com ±³À°Á¾·ù : ºñ´¢ÀÇÇаú Âü¼®¿¹»óÀοø : 200¸í Áö¿ª : ¼¿ïƯº°½Ã ¼¼ºÎ¼ö°·á : 30,000¿ø ºñ°í Àü¹®ÀÇ: 30,000¿ø / Àü°øÀÇ, ±ºÀÇ°ü, °£È£»ç: 20,000¿ø
±âŸ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 08:10~08:40 Registration () ±âŸ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 08:40~09:00 President¡¯s Welcome () ±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 09:00~09:20 Introducing PI-QUAL (Prostate Imaging Quality) Score Àå¿ø(ÀüºÏÀÇ´ë ¿µ»óÀÇÇаú) ±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 09:20~09:40 AI (Artificial Intelligence) application ±èÂù±³(¼º±Õ°üÀÇ´ë ¿µ»óÀÇÇаú) ±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 09:40~09:57 Role of metastatectomy in RCC: Where do we stand? ¹ÚÁø¼º(À»ÁöÀÇ´ë ºñ´¢ÀÇÇаú) ±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 09:57~10:14 Which approach is better for 1st line treatment in mRCC ½Å»óÁØ(¿¬¼¼ÀÇ´ë Á¾¾ç³»°ú) ±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 10:14~10:30 SBRT on renal cell carcinoma: an overview of technical aspects and biological rationale ÀÓÁÖÇÑ(ÀÎÇÏÀÇ´ë Á¾¾ç³»°ú) ÈÞ½Ä 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 10:30~10:50 Break () ±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 10:50~11:20 Genomic Testing and treatment with PARP-inhibitors in Patients with MetastaticCastration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians in view of the recent data Axel Merseburger MD PhD((University Hospital Schleswig-HolsteinLübeck Germany) ±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 11:20~11:37 Role of the prostate- and/or metastasis-directed radiation for oligometastatic HSPC ±Ç¹Î¼±(¾ÆÁÖÀÇ´ë Á¾¾ç³»°ú) ±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 11:37~11:54 Surgery for micro-metastatic HSPC diagnosed by PSMA PET/CT after definitive treatment ±è¼ºÈ¯(°¡Å縯ÀÇ´ë ¹æ»ç¼±Á¾¾çÇаú) ±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 11:54~12:10 Update in the systemic management for low volume mHSPC ÀÌÈ¿Áø(Ãæ³²ÀÇ´ë Á¾¾ç³»°ú) ½Ä»ç 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 12:10~13:40 Lunch () ±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 13:40~14:00 Role of surgery in metastatic PPGL ±è¿Ï¼®(ÀÌÈÀÇ´ë ºñ´¢ÀÇÇаú) ±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 14:00~14:20 Newer diagnostic & therapeutic modalities in PPGL ±è¿¬ÁÖ(¿ï»êÀÇ´ë ¹æ»ç¼±Á¾¾çÇаú) ±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 14:20~14:50 PSMA Targeted Radioligand Therapy: Current Status and Future Directions Phillip Koo MD FACS(Division Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Arizona) ÈÞ½Ä 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 14:50~15:10 Break () ±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 15:10~15:30 Kidney ÀÌÁ¤Çö(°í·ÁÀÇ´ë º´¸®°ú) ±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 15:30~15:50 Urinary bladder and prostate Ȳ¼öÇö(¼º±Õ°üÀÇ´ë º´¸®°ú) ±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 15:50~16:10 Treatment of Huge Non-muscle invasive bladder cancer without high grade ±¸ÀÚÇö(¼¿ïÀÇ´ë ºñ´¢ÀÇÇаú) ±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 16:10~16:30 Radiation therapy for BCG-unresponsive NMIBC ±èÀÎÈ£(°¡Å縯ÀÇ´ë Á¾¾ç³»°ú) ±âŸ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 16:30~16:40 Çмú»ó ½Ã»ó½Ä () ±âŸ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 16:40~17:10 Æóȸ ¹× ÃÑȸ ()
|
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|